Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (41-50 of 335) with videos related to

Pageof 34
Sort By:
Human Vaccines & Immunotherapeutics|April 21, 2021
Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trialsMelissa Bersanelli, Fausto Petrelli, Sebastiano Buti, et al.
BMC Cancer|August 14, 2016
Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case reportPaola Bordi, Marcello Tiseo, Giorgio Baldari, et al.
Oncology Reviews|May 21, 2015
Systemic adjuvant therapies in renal cell carcinomaSebastiano Buti, Melissa Bersanelli, Maddalena Donini, et al.
Seminars in Oncology|November 16, 2019
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patientsAlessio Cortellini, Sebastiano Buti, Veronica Agostinelli, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2021
Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapyAlessio Cortellini, Melissa Bersanelli, David J Pinato, et al.
Minerva Urology and Nephrology|December 21, 2023
Wolf in sheep's clothing or not? The pT1 LG dilemmaGiulia C Giudice, Davide Campobasso, Umberto Maestroni, et al.
Therapeutic Advances in Medical Oncology|June 20, 2020
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic reviewMelissa Bersanelli, Matteo Brunelli, Letizia Gnetti, et al.
Current Drug Targets|January 14, 2016
Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case ReportMelissa Bersanelli, Francesco Facchinetti, Marcello Tiseo, et al.
Annals of Translational Medicine|April 30, 2019
Pathological nodal staging score for renal cell carcinoma: how to build reliable therapeutic choices basing on assumptionsMelissa Bersanelli, Sebastiano Buti, Matteo Santoni, et al.
Anti-Cancer Drugs|January 10, 2020
A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick?Melissa Bersanelli, Sebastiano Buti, Antonio Ghidini, et al.
Pageof 34

Showing results (41-50 of 335) with videos related to

Sort By:
Pageof 34
Human Vaccines & Immunotherapeutics|April 21, 2021
Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trialsMelissa Bersanelli, Fausto Petrelli, Sebastiano Buti, et al.
BMC Cancer|August 14, 2016
Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case reportPaola Bordi, Marcello Tiseo, Giorgio Baldari, et al.
Oncology Reviews|May 21, 2015
Systemic adjuvant therapies in renal cell carcinomaSebastiano Buti, Melissa Bersanelli, Maddalena Donini, et al.
Seminars in Oncology|November 16, 2019
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patientsAlessio Cortellini, Sebastiano Buti, Veronica Agostinelli, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2021
Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapyAlessio Cortellini, Melissa Bersanelli, David J Pinato, et al.
Minerva Urology and Nephrology|December 21, 2023
Wolf in sheep's clothing or not? The pT1 LG dilemmaGiulia C Giudice, Davide Campobasso, Umberto Maestroni, et al.
Therapeutic Advances in Medical Oncology|June 20, 2020
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic reviewMelissa Bersanelli, Matteo Brunelli, Letizia Gnetti, et al.
Current Drug Targets|January 14, 2016
Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case ReportMelissa Bersanelli, Francesco Facchinetti, Marcello Tiseo, et al.
Annals of Translational Medicine|April 30, 2019
Pathological nodal staging score for renal cell carcinoma: how to build reliable therapeutic choices basing on assumptionsMelissa Bersanelli, Sebastiano Buti, Matteo Santoni, et al.
Anti-Cancer Drugs|January 10, 2020
A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick?Melissa Bersanelli, Sebastiano Buti, Antonio Ghidini, et al.
Pageof 34